Verastem Oncology develops and commercializes novel therapies for RAS/MAPK pathway-driven cancers, including treatments targeting KRAS G12D, RAF/MEK, and FAK.
Verastem Oncology develops and commercializes novel therapies for RAS/MAPK pathway-driven cancers, including treatments targeting KRAS G12D, RAF/MEK, and FAK.